Related Experiment Video

Updated: Jul 11, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell

Benedict Chambers1, Per Grufman, Vanoohi Fredriksson

  • 1Center for Infectious Medicine, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden. Benedict.Chambers@ki.se

Cancer Research
|September 19, 2007
PubMed

Insights

This study explores a novel cancer therapy targeting tumors with impaired antigen processing. Dendritic cells engineered to present specific T cell epitopes (TEIPP) effectively protected mice against cancer, suggesting a new treatment strategy for antigen processing-deficient cancers.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Immunology

Background:

  • Many human cancers evade immune detection due to defects in MHC class I antigen processing.
  • These defects allow tumors to resist destruction by cytotoxic T lymphocytes (CTLs).
  • Tumor immune escape variants present unique T cell epitopes associated with impaired peptide processing (TEIPP).

Purpose of the Study:

  • To investigate the therapeutic potential of a dendritic cell (DC)-based vaccine targeting TEIPP antigens.
  • To explore the use of TAP-inhibited DCs for treating antigen processing-deficient cancers.

Main Methods:

  • Dendritic cells (DCs) with impaired TAP function were generated to present endogenous TEIPP antigens.
  • Mice were immunized with these engineered DCs and challenged with TAP-deficient tumors.
  • Immune responses were analyzed, focusing on CTL activity and the role of CD8+ cells.
  • Wild-type DCs were treated with a viral TAP inhibitor (UL49.5) to induce TEIPP antigen presentation.

Main Results:

  • Immunization with TAP-impaired DCs conferred protection against TAP-deficient lymphomas and fibrosarcomas in mice.
  • Vaccinated mice exhibited robust TEIPP-specific CTL responses, with CD8+ cells playing a critical role in tumor resistance.
  • TEIPP antigens were successfully induced in wild-type DCs using the viral TAP inhibitor UL49.5.

Conclusions:

  • Dendritic cell-based vaccines targeting TEIPP antigens show promise for treating tumors with antigen processing deficiencies.
  • Targeting TEIPP antigens via TAP-inhibited DCs represents a viable immune intervention strategy for antigen processing-deficient cancers.
  • This approach could lead to new treatments for human cancers exhibiting MHC class I antigen-processing machinery defects.

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...